CN109069603A - 全细胞癌症疫苗及其选择方法 - Google Patents

全细胞癌症疫苗及其选择方法 Download PDF

Info

Publication number
CN109069603A
CN109069603A CN201780023982.8A CN201780023982A CN109069603A CN 109069603 A CN109069603 A CN 109069603A CN 201780023982 A CN201780023982 A CN 201780023982A CN 109069603 A CN109069603 A CN 109069603A
Authority
CN
China
Prior art keywords
hla
gene
cell
allele
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780023982.8A
Other languages
English (en)
Chinese (zh)
Inventor
马库斯·丹尼尔·拉彻
约瑟夫·保罗·瓦格纳
查尔斯·路易斯·怀斯曼
威廉·瓦伦蒂恩·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Briacell Therapeutics Corp USA
Original Assignee
Briacell Therapeutics Corp USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Briacell Therapeutics Corp USA filed Critical Briacell Therapeutics Corp USA
Publication of CN109069603A publication Critical patent/CN109069603A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/00112—Receptors for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780023982.8A 2016-02-25 2017-02-27 全细胞癌症疫苗及其选择方法 Pending CN109069603A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662299674P 2016-02-25 2016-02-25
US62/299,674 2016-02-25
US201662425027P 2016-11-21 2016-11-21
US62/425,027 2016-11-21
PCT/US2017/019757 WO2017147600A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Publications (1)

Publication Number Publication Date
CN109069603A true CN109069603A (zh) 2018-12-21

Family

ID=59685619

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780023982.8A Pending CN109069603A (zh) 2016-02-25 2017-02-27 全细胞癌症疫苗及其选择方法

Country Status (9)

Country Link
US (2) US11559574B2 (https=)
EP (1) EP3419657A4 (https=)
JP (1) JP6901505B2 (https=)
CN (1) CN109069603A (https=)
AU (3) AU2017224232B2 (https=)
CA (2) CA3015080A1 (https=)
IL (1) IL261354A (https=)
NZ (1) NZ745327A (https=)
WO (1) WO2017147600A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118207320A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-c*04:01基因的新用途及检测试剂盒

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof
CN111386042B (zh) * 2017-12-04 2023-01-31 热生物制品有限公司 基于细胞的疫苗的生产
JP2021507924A (ja) * 2017-12-22 2021-02-25 ディストリビューテッド バイオ， インコーポレイテッド 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法
CN108175853A (zh) * 2018-01-24 2018-06-19 上海赛群生物科技有限公司 一种肿瘤细胞疫苗及其制备方法
CN108486038B (zh) * 2018-03-21 2021-08-27 中国人民解放军第四军医大学 一种构建脂肪干细胞膜片的方法及应用
WO2020132595A1 (en) * 2018-12-21 2020-06-25 The Regents Of The University Of California Il-10-containing vaccines and uses thereof
TW202134430A (zh) 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗
CN110938630B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人b3gnt5基因的用途及相关产品
WO2023092053A1 (en) * 2021-11-18 2023-05-25 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based cancer treatments
WO2023167973A1 (en) 2022-03-03 2023-09-07 Briacell Therapeutics Corp. Cancer vaccines and methods of use thereof
CN115433734B (zh) * 2022-06-01 2025-03-04 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用
CN117990593A (zh) * 2024-01-31 2024-05-07 南昌铭硕生科生物工程有限公司 一种流式多因子分析系统及其分析方法
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof
CN118207319A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-a*03:04基因的新用途及检测试剂盒
WO2026068517A1 (en) * 2024-09-24 2026-04-02 Universiteit Gent Cancer immunotherapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750102A (en) * 1992-03-13 1998-05-12 Yeda Research And Development Co., Ltd. Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
US6149905A (en) * 1993-11-03 2000-11-21 Genetics Institute, Inc. Tumor cells with increased immunogenicity and uses therefor
US20050276822A1 (en) * 2004-06-14 2005-12-15 Charles Wiseman Novel breast cancer cell lines and uses thereof
WO2006135454A1 (en) * 2005-06-08 2006-12-21 Saint Vincent Medical Center, A California Corporation Novel cancer cell lines and uses thereof
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2012156969A1 (en) * 2011-05-17 2012-11-22 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050589A1 (en) * 1999-02-22 2000-08-31 Ludwig Institute For Cancer Research TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES
US20130052215A9 (en) * 2003-09-26 2013-02-28 Eckhard Podack Tumor vaccine
WO2006081629A1 (en) 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy.
US20080020386A1 (en) 2006-03-29 2008-01-24 Medigen Biotechnology Corporation Methods and apparatus for genotyping
US8969254B2 (en) * 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750102A (en) * 1992-03-13 1998-05-12 Yeda Research And Development Co., Ltd. Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
US6149905A (en) * 1993-11-03 2000-11-21 Genetics Institute, Inc. Tumor cells with increased immunogenicity and uses therefor
US20050276822A1 (en) * 2004-06-14 2005-12-15 Charles Wiseman Novel breast cancer cell lines and uses thereof
WO2006135454A1 (en) * 2005-06-08 2006-12-21 Saint Vincent Medical Center, A California Corporation Novel cancer cell lines and uses thereof
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2012156969A1 (en) * 2011-05-17 2012-11-22 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118207320A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-c*04:01基因的新用途及检测试剂盒

Also Published As

Publication number Publication date
AU2017224232B2 (en) 2022-07-28
AU2017224232A1 (en) 2018-09-06
NZ745327A (en) 2023-06-30
US20190046624A1 (en) 2019-02-14
JP6901505B2 (ja) 2021-07-14
IL261354A (en) 2018-10-31
EP3419657A1 (en) 2019-01-02
AU2022259857A1 (en) 2022-12-08
US11559574B2 (en) 2023-01-24
AU2025205094A1 (en) 2025-07-24
JP2019507608A (ja) 2019-03-22
AU2022259857B2 (en) 2025-05-29
US20230277640A1 (en) 2023-09-07
NZ785587A (en) 2025-02-28
WO2017147600A1 (en) 2017-08-31
EP3419657A4 (en) 2019-11-06
CA3015080A1 (en) 2017-08-31
CA3300406A1 (en) 2026-03-02

Similar Documents

Publication Publication Date Title
CN109069603A (zh) 全细胞癌症疫苗及其选择方法
Hegde et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer
US11369668B1 (en) Tumor cell vaccines
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
Robertson et al. Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer
JP2020530277A (ja) 反復投与のための細胞免疫療法
JP2026049725A (ja) 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム
CN109477149A (zh) 选择新表位作为具有增强效力的用于治疗的疾病特异性靶标
US20220298222A1 (en) Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
Lacher et al. SV-BR-1-gm, a clinically effective GM-CSF-Secreting breast cancer cell line, expresses an immune signature and directly activates CD4+ T lymphocytes
US20250201339A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
US20250134977A1 (en) Tumor cell vaccines
US20220133868A1 (en) Tumor cell vaccines
US20250032617A1 (en) Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers
CN119677852A (zh) 抑制信号调节蛋白α(SIRPα)基因表达的组合物和方法
Beck et al. An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy
Khandelwal et al. Alemtuzumab for Steroid Refractory Acute Graft Versus Host Disease in Pediatric Patients: A Retrospective Review of 12 Patients Reveals a Response Rate of 83%
EA046410B1 (ru) Иммуногенетическая скрининговая проба на рак

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination